Mictasol

Quick links to important sections

Mictasol

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mictasol

Quick Facts

Property Description
Active ingredient Norfloxacin, Phenazopyridine
Form Oral Tablet
Pharmacological class Antimicrobial Agent, Urinary Analgesic
Common use Urinary Tract Infection (UTI) Management
Origin Synthetic, Chemically Derived

What Type of Medicine is Mictasol?

Mictasol is a synthetic fixed-dose combination product classified as a prescription medicine that integrates two distinct pharmacological agents into a single oral tablet preparation. The drug is classified as a dual-action agent, combining an antimicrobial agent with a urinary analgesic. This formulation is designed for the comprehensive management of patients with suspected or confirmed bacterial urinary tract infections (UTIs). The use of a fixed-dose combination provides an approach distinct from single-entity preparations by combining multiple therapeutic actions. This integrated structure is primarily positioned for use in adult patient groups.

Composition: The Dual Action of Norfloxacin and Phenazopyridine

The core structure of Mictasol relies on the synergy between its two active ingredients: Norfloxacin and Phenazopyridine. Norfloxacin is an established fluoroquinolone antibiotic, a class of antimicrobial agents recognized for their bactericidal properties against a wide spectrum of uropathogens. Phenazopyridine, conversely, is an azo dye classified as a pyridium derivative that acts specifically as a urinary analgesic. This combined formulation is a key differentiating factor, as it means the product addresses both the microbial cause of the UTI and the acute pain associated with it, offering relief not provided by Norfloxacin alone.

General Purpose: Simultaneous Treatment and Symptom Relief

The general purpose of Mictasol is to offer an integrated approach to managing UTIs by coupling infection control with pain mitigation. Phenazopyridine is intended to alleviate symptoms like dysuria (painful urination), burning, urgency, and frequency linked to lower UTIs. This helps quickly relieve the burning and pain while the antibiotic begins its therapeutic action. The preparation provides the benefit of simultaneous treatment and symptom relief, ensuring that the bacterial pathogen is targeted while rapid patient comfort is achieved. This combined strategy makes it a common therapeutic choice when both effective pathogen elimination and swift symptomatic relief are required.

Regulatory References

  1. Norfloxacin - LiverTox - NCBI Bookshelf - NIH
  2. Phenazopyridine - StatPearls - NCBI Bookshelf - NIH

What side effects are possible with Mictasol?

Possible Side Effects and Safety Information

The official safety profile for Mictasol, a combination of Norfloxacin and Phenazopyridine, is derived from the established risk profiles of its two active components. Adverse reactions are classified by regulatory agencies according to their documented frequency and affected physiological system.

Common adverse reactions typically include gastrointestinal effects like nausea and diarrhea, and central nervous system effects such as headache and dizziness. Uncommon and rare events are also documented, often involving the nervous system and skin.


Documented Serious Adverse Reactions

The label documents serious adverse reactions, primarily linked to the fluoroquinolone (Norfloxacin) component. These include serious neurological events such as Peripheral Neuropathy (which may be persistent or irreversible) and Convulsions/Seizures. Potentially life-altering musculoskeletal events like Tendon Rupture are also officially noted. Severe hypersensitivity and hematological events, such as Methemoglobinemia and Hemolytic Anemia (linked to Phenazopyridine), are also recognized as rare, serious risks.


Safety Considerations and Restrictions

Specific safety considerations are defined for certain populations. Older adults and individuals with impaired renal function are officially documented as being at an increased risk of tendon problems and drug accumulation. The risk of tendon complications is also heightened by the co-administration of corticosteroids.

The medicine is formally contraindicated in patients with a history of hypersensitivity to quinolones or with severe renal or hepatic disease. Due to the Phenazopyridine component, the official label notes an expected reddish-orange discoloration of urine; however, a yellowish discoloration of the skin or eyes is documented as a safety signal indicating potential accumulation and toxicity.

Overdose and Emergency Response

Overdose and when to seek help

This information reflects the official, non-advisory instructions detailed in regulatory documents for managing a suspected overdose.

Immediate Emergency Action

If a Mictasol overdose is suspected, users and caregivers are required to contact a Poison Control Center or emergency services immediately. This action is explicitly mandated across authoritative drug labeling. Immediate medical attention must be sought if any serious clinical manifestations occur, such as severe dizziness, fainting, difficulty breathing, or chest pain.

Overdose Domain Regulatory Statement
Symptom Recognition No specific symptom clusters are universally documented in the public-facing Overdose section; management is based on supportive care for the clinical signs present.
Treatment Focus Management is primarily supportive and symptomatic; no specific pharmacologic antidote is universally listed in regulatory prescribing information.
Monitoring Continuous observation and monitoring of the patient's physiological status, including necessary laboratory tests, are warranted in a medical facility.

Official Profile Summary

The regulatory profile establishes the threshold for seeking urgent care by explicitly stating that any suspected overdose requires immediate professional intervention. The documented instructions direct healthcare providers to focus on supportive treatment, emphasizing patient monitoring and symptomatic management to address any resulting clinical changes.

Therapeutic Uses of Mictasol

What Mictasol Treats: Main Uses and Benefits

This medication is commonly used to help with acute urinary tract infections (UTIs) and is considered relevant in clinical settings that involve acute or disruptive symptom patterns. It is applied across domains where additional symptomatic support for the condition is needed.

The medicine may assist with easing painful and distressing symptoms related to physical discomfort in the urinary tract, such as burning pain, urgency, and frequency. It is applied when appropriate when patients experience these uncomfortable symptoms. This type of drug is indicated for the symptomatic relief of pain, burning, urgency, frequency, and other discomforts arising from irritation of the lower urinary tract mucosa.

The symptomatic relief offers support that helps patients cope more steadily with difficult episodes. The support provided for the condition and the easing of symptoms contributes to easing the overall symptom load. This approach assists with maintaining functional stability when symptoms are more noticeable and provides supportive relief when symptoms interfere with routine activities.

Quick Fact: This medication is relevant for easing symptoms that create noticeable functional strain during acute episodes.

Regulatory References

  1. Phenazopyridine Hydrochloride Labeling

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Mictasol — Official Regulatory Information

The eligibility for Mictasol, a fixed-dose combination of Norfloxacin and Phenazopyridine, is determined by the regulatory restrictions applied to both active components. Eligibility is defined by the following classifications:

Category Official Regulatory Statement
Populations for whom use is allowed Adult patients for whom the combination is deemed appropriate.
Populations for whom use is contraindicated Patients with pre-existing renal insufficiency, severe liver disease, severe hepatitis, or pyelonephritis of pregnancy (Phenazopyridine component).
Patients with known hypersensitivity to Norfloxacin, Phenazopyridine, or any fluoroquinolone-class drug.
Patients with a history of tendinitis, tendon rupture, or myasthenia gravis (Norfloxacin component).
Age-related eligibility rules Pediatric population (under 18 years old): Safety and efficacy have not been established; use is not recommended.
Older adults: Use is permitted but requires caution due to the common age-related decline in renal function, which can cause drug accumulation.
Pregnancy and lactation eligibility status Pregnancy: Should be used only if the benefit clearly outweighs the risk, as adequate human studies are lacking.
Lactation/Breastfeeding: Not recommended; a decision should be made to discontinue nursing or discontinue the drug.
Eligibility-related restrictions Patients with G-6-PD deficiency require cautious use due to a potential predisposition to hemolysis.

Connection to the overall eligibility profile

Regulatory documents establish a clear framework for Mictasol by strictly defining absolute non-eligibility based on severe organ impairment (renal, hepatic) and specific adverse histories (tendon rupture, myasthenia gravis). Eligibility is restricted or conditionally managed in children due to unestablished safety and in pregnancy and lactation due to insufficient human data, ensuring that use aligns solely with populations where the regulatory risk profile is officially documented as acceptable or conditionally managed.

What should I know about interactions with other medicines?

Mictasol is a combination product containing Norfloxacin (a fluoroquinolone antibacterial) and Phenazopyridine. The interaction profile of Mictasol is derived from the known or potential interactions of these two active components.

Interacting Medicinal Products and Categories

Active Component Interacting Products / Categories Interaction-Related Conditions
Norfloxacin Antiarrhythmics (Class IA, Class III) Concomitant use with drugs that prolong the QTc interval should be avoided or used with caution due to risk of cardiac effects.
Warfarin and derivatives May enhance the effect of oral anticoagulants, requiring careful INR monitoring.
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) May increase the risk of central nervous system (CNS) stimulation and convulsive seizures. Use with caution.
Multivitamins, Antacids, Sucralfate, Didanosine Products containing magnesium, aluminum, iron, or zinc should not be taken within two hours of Norfloxacin administration, as they can significantly reduce its absorption and efficacy.
Theophylline, Caffeine Norfloxacin may interfere with their metabolism, leading to elevated concentrations and potential toxicity.
Phenazopyridine Interference with laboratory tests Phenazopyridine and its orange-red metabolite can interfere with colorimetric, spectrophotometric, and fluorometric methods of urinalysis and other lab tests.

Norfloxacin should be used with caution in patients taking drugs that affect the QTc interval, such as tricyclic antidepressants or certain antipsychotics.

Mechanism of Action

How Mictasol Works: Mechanism of Action

Formaldehyde-Mediated Disruption of Bacterial Integrity

This mechanism involves the Methenamine component, a prodrug that requires an acidic pH within the urine to hydrolyze into formaldehyde. Formaldehyde then acts as a non-specific cytotoxic agent, targeting and denaturing essential bacterial proteins and nucleic acids. This molecular action results in the inhibition of bacterial proliferation and viability within the urinary tract.


Inhibition of Prostaglandin Synthesis for Pathway Modulation

Concurrently, the Salicylate component operates by non-selectively inhibiting Cyclooxygenase (COX) enzymes. This key interaction blocks the enzymatic conversion that synthesizes prostaglandins, which are lipid mediators central to peripheral pain signaling and inflammation. The resulting cascade consequence is the reduced sensitization of peripheral nociceptors and a dampening of localized inflammatory signaling.


Integrated Dual-Pathway Mechanistic Influence

The integration of these two mechanisms influences two independent physiological systems: microbial proliferation and the host's inflammatory response, resulting in a convergent physiological effect on the lower urinary tract.

Dosage and Administration Information

How to Use Mictasol

Mictasol is an oral tablet combining an antimicrobial agent and a urinary analgesic. The medicine is intended to be swallowed by the oral route with a full glass of water.


Official Dosing and Schedule

Standard adult use involves a divided frequency due to the dual composition. The antimicrobial component (Norfloxacin) is typically prescribed at 400 mg and taken twice daily (every 12 hours) for the duration of the treatment course. The analgesic component (Phenazopyridine), usually 200 mg, is scheduled for administration three times daily (TID).


Administration Conditions and Duration

The most important constraint is the time-bound duration of the analgesic. The Phenazopyridine component is used for a maximum of two days. After the initial two-day period, the antimicrobial component continues alone for its prescribed duration, which may range from 3 to 21 days depending on the type of urinary tract infection.

Regarding timing, the Phenazopyridine component is often instructed to be taken with or immediately following food to help reduce gastric irritation. Furthermore, the medication must not be taken concurrently with products containing iron, zinc, or antacids, requiring a separation of at least two hours to maintain optimal absorption of the antimicrobial agent.


Use in Specific Populations

Administration is contingent upon renal function. In cases of significant renal impairment (Creatinine Clearance less than or equal to 30 mL/min), the dose of the antimicrobial component is typically reduced to 400 mg once daily. The Phenazopyridine component is contraindicated in patients with renal insufficiency.

Recent Clinical Evidence

Research evidence / Overview of Studies for Mictasol

Evidence for Clearing the Underlying Infection (Norfloxacin Component)

Research exploring the antibiotic component (Norfloxacin) was studied for use in acute bacterial urinary tract infections (UTIs), particularly those that are uncomplicated or recurrent. Randomized Controlled Trials (RCTs) and comparative clinical studies were evaluated in order to understand how the medicine was studied for its role in relation to the bacterial cause of these infections. Studies monitored primary outcomes such as the patient's bacteriological status—that is, the measurements related to bacterial presence in the urine—and the patient's clinical status, which involves tracking the resolution or change in urinary symptoms. Regulatory assessments documented patterns in findings derived from comparative trials.

Uncertainty remains regarding the extent of the evidence for its use in more complex cases. Regulatory evaluations have noted the lack of sufficient evidence to support its use in certain complicated infections, such as those affecting the kidneys (pyelonephritis). Findings were mixed or inconsistent across certain study populations or time periods.

Evidence for Rapid Symptom Relief (Phenazopyridine Component)

The evidence base for the analgesic component (Phenazopyridine) was studied for its role related to short-term acute discomfort. Placebo-controlled trials have been applied in studies examining patient-reported experiences of pain, burning, and urgency associated with lower UTI symptoms. Studies monitored this component’s use specifically as an adjuvant (helper) in research where it was used concurrently with an antibiotic for acute symptomatic episodes.

What remains uncertain is the scope beyond its defined use. Research confirms the component’s function is strictly symptomatic, and it was not studied for use as a means of infection clearance. Due to its intended purpose, the observation period for primary outcomes in studies is very short-term (typically within 6 to 48 hours), and there is limited information for long-term outcomes or utility of this component beyond the typically limited, short duration of use (e.g., two days).

What is Still Uncertain About the Research

Evidence quality varies across studies, and regulators have identified several areas where data remain insufficient. Limited information for long-term outcomes is a known feature, as most trials focus on short-term eradication and acute relief. Data for specific groups, such as pediatric or pregnant populations, remain insufficient and are not well characterized. Study results reflect the specific conditions under which they were conducted, and are not individual predictions.

Key Studies & References

  1. Efficiency and safety of phenazopyridine for treatment of uncomplicated urinary tract infection: results of multi-center, randomized, placebo-controlled, clinical study
  2. Review of norfloxacin in lower urinary tract infections (Systematic Review)
  3. Phenazopyridine: MedlinePlus Drug Information (NIH Monograph)

Frequently Asked Questions (FAQ)

Common questions about Mictasol (FAQ)


Q: How quickly should I expect to feel an improvement after starting Mictasol?

A: Mictasol contains an analgesic component (Phenazopyridine) that acts as a local anesthetic, which is intended to provide prompt relief from pain, burning, and urgency. Studies and official information indicate that relief from these symptoms may be felt within hours of taking the first dose. The analgesic component is typically recommended for short-term use, generally up to two days, while the antibiotic component continues its therapeutic action.

Q: Are there any specific foods or drinks that should be avoided while taking Mictasol?

A: Official product information advises separating Mictasol from certain mineral-containing products. Specifically, the antibiotic component (Norfloxacin) can be affected by products containing magnesium, aluminum, iron, or zinc, as they can reduce the drug’s effectiveness. It is important to separate the administration of Mictasol from these products by at least two hours. There are no general food or drink restrictions explicitly listed in the major component labels.

Q: Can Mictasol increase sensitivity to the sun or cause a severe sunburn?

A: Yes, official safety information indicates that the Norfloxacin component of Mictasol is associated with a risk of photosensitivity, which is an increased sensitivity to sunlight or ultraviolet (UV) light. Due to this risk, minimizing exposure to sunlight and UV light is a recommended precaution while using this medication.

Q: Can Mictasol interact with caffeine, and if so, how?

A: Yes, regulatory documents indicate that the Norfloxacin component may interfere with the body's breakdown (metabolism) of caffeine. This can lead to elevated levels of caffeine in the bloodstream, which may result in symptoms of potential toxicity.

Q: Can Mictasol affect blood sugar levels, and is this a concern for diabetics?

A: Official labels note a specific caution for patients with a deficiency of the enzyme Glucose-6-Phosphate Dehydrogenase (G6PD). This is because the Phenazopyridine component may cause a rare hemolytic reaction (breakdown of red blood cells) in these individuals.

Q: Can Mictasol cause temporary or permanent changes to vision?

A: The official product labeling for the antibiotic component (Norfloxacin) lists potential disturbances to special senses, including blurred vision. Additionally, the Phenazopyridine component has been associated with visual disturbances, which are usually reported in cases of drug accumulation or overdose.

Q: How does Mictasol affect the good bacteria in the gut, and can I take probiotics with it?

A: As Mictasol contains an antimicrobial agent, its purpose is to kill bacteria, which can affect the normal balance of healthy bacteria in the body, including the gut microbiome. While this can sometimes lead to diarrhea, official regulatory documents do not provide specific guidance on whether to take probiotics while using Mictasol.

Q: Can Mictasol make you feel more anxious or nervous?

A: Yes, regulatory reports for the Norfloxacin component have documented central nervous system (CNS) effects. These effects include both anxiety and nervousness as reported adverse experiences.

Q: Is there any research on Mictasol's safety during pregnancy or breastfeeding?

A: Official safety documents state that there are no adequate and well-controlled human studies on the drug's use during pregnancy. Therefore, its use is generally considered only if the potential benefit clearly outweighs the potential risk. Furthermore, use is not recommended while breastfeeding, as the drug may pass into human milk.

Q: What kind of monitoring (e.g., blood tests) might be needed while on a Mictasol course?

A: Regulatory information indicates that specific blood monitoring may be required if Mictasol is taken with certain other drugs. For instance, patients taking the anticoagulant warfarin concurrently with Norfloxacin require careful monitoring of the International Normalized Ratio (INR). Monitoring may also be considered for patients with G6PD deficiency.

Q: What is the main difference between Mictasol and other antibiotics commonly used for urinary issues?

A: The primary difference is that Mictasol is a fixed-dose combination product containing two active components: the antibiotic Norfloxacin and the urinary analgesic Phenazopyridine. This formulation is designed to address both the microbial infection and the acute symptoms like pain and burning. Most other common UTI treatments are single-agent antibiotics.

Q: Is Mictasol typically prescribed for more than just a standard UTI?

A: Yes, official indications for the Norfloxacin component include the treatment of certain complex urinary tract infections, as well as specific infections of the prostate gland (prostatitis) and some sexually transmitted infections like gonorrhea.

Q: Is Mictasol a type of penicillin, or what class of antibiotic does it belong to?

A: Mictasol contains the active ingredient Norfloxacin, which belongs to the fluoroquinolone class of antibiotics. It is important to know that this drug is not a penicillin-class antibiotic.

Q: Why is the purpose of the full glass of water requirement when taking Mictasol tablets?

A: The instruction to take the tablets with a full glass of water relates to the antibiotic component (Norfloxacin). Regulatory documents recommend adequate fluid intake to minimize the risk of a condition called crystalluria, where crystals can form in the urine.

Q: What should I do if I accidentally miss a dose of Mictasol?

A: If a dose is missed, official guidance often recommends taking it as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the missed dose is usually skipped, and the regular schedule is resumed. Double doses are generally advised against.

Q: Is it necessary to take Mictasol at the exact same time every day?

A: Official instructions for the Norfloxacin component recommend it be taken twice daily (every 12 hours). Taking the dose at regular, consistent intervals helps maintain a steady level of the antibiotic in the body, which is important for effectively treating the bacterial infection.

Q: Does Mictasol interact with any common supplements like vitamins or herbal remedies?

A: The antibiotic component (Norfloxacin) is known to specifically interact with products containing magnesium, aluminum, iron, or zinc, which are common ingredients in multivitamins and supplements. It is important to separate the administration of Mictasol from these products by at least two hours. Interactions with other herbal remedies are not always specified in the core documents.

Q: Why are people with a history of seizures advised to be cautious with Mictasol?

A: Official product information for Norfloxacin highlights that it is associated with disorders of the central nervous system. The drug can potentially lower the seizure threshold, meaning it may increase the risk of a seizure. Convulsions have been reported as a rare but serious adverse event.

Q: Why do some forums mention Mictasol being used for prostatitis?

A: The reason Mictasol is mentioned for prostatitis (inflammation of the prostate gland) is that its antibiotic component, Norfloxacin, is indicated and officially used for the treatment of this type of infection in men.

Q: What is the difference between a quinolone and a fluoroquinolone, in the context of Mictasol?

A: A fluoroquinolone is a subclass of quinolone antibiotics. The term 'fluoro' refers to the fluorine atom added to the chemical structure of the drug. Norfloxacin is a fluoroquinolone, and this modification generally provides it with a broader range of antibacterial activity.

Q: Why do some people on social media recommend avoiding sun exposure completely while on Mictasol?

A: This caution is likely due to the risk of photosensitivity associated with the Norfloxacin component. Because this reaction can potentially lead to severe sunburn or skin reactions, official guidance advises patients to avoid excessive exposure to the sun or UV light.

Q: What is the shelf life of Mictasol tablets, and how should they be stored?

A: Official storage instructions require that the tablets be kept at Controlled Room Temperature and protected from both light and moisture in a tightly closed container. The specific expiration date or numerical shelf-life is product-specific and must be checked on the original container, as it is not stated in general regulatory texts.

Q: Is it normal to have mild joint pain while taking Mictasol?

A: The most severe musculoskeletal risk documented is tendon rupture, a serious, but rare, adverse event associated with the antibiotic component (Norfloxacin). Official documents do not typically quantify mild joint pain as a common side effect. Any new or worsening pain in the joints or tendons is important to monitor.

Q: What is the likelihood of a serious side effect, like C. difficile diarrhea, with Mictasol?

A: Like many antibiotics, Mictasol carries a potential risk of an overgrowth of bacteria that can cause a severe form of diarrhea known as Clostridioides difficile-associated diarrhea (CDAD). Although the likelihood is not precisely quantified in core documents, the risk is recognized for this class of antibiotics.

Q: Can Mictasol be used to prevent infections, or is it only for treatment?

A: Official regulatory documents indicate that the antibiotic component, Norfloxacin, is approved and used for the treatment of established bacterial infections. It is not generally indicated for the prevention (prophylaxis) of infections.

Q: Why might a doctor prescribe a longer course of Mictasol (e.g., three weeks) instead of a short one?

A: The length of the treatment course depends on the specific type and severity of the infection being treated. For complex or chronic infections, such as prostatitis, the recommended duration for the Norfloxacin component is significantly longer—sometimes up to 28 days (four weeks)—than for an uncomplicated urinary tract infection.

Q: What are the possible long-term effects of taking Mictasol?

A: The official product label documents several serious adverse reactions primarily linked to the antibiotic component (Norfloxacin). These include Peripheral Neuropathy (nerve damage) which may be persistent or irreversible, and potentially life-altering musculoskeletal events like Tendon Rupture.

How should Mictasol be stored and disposed of?

How to Store and Dispose of Mictasol?

Mictasol (Norfloxacin/Phenazopyridine) must be stored strictly according to regulatory specifications to maintain product integrity.


Storage Requirements

The tablets require storage at Controlled Room Temperature, defined as 20 to 25 C (68 to 77 F), with excursions up to 30 C permitted. The medication must be kept from freezing and protected from both light and excess moisture. Store the product in a tight container, kept tightly closed.


Safety and Disposal

It is mandatory to keep Mictasol out of the sight and reach of children. Do not keep outdated medicine or medicine no longer needed. For disposal of any unused portions, patients are instructed to consult their healthcare professional for guidance on the proper protocol.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mictasol found in:

A-Z Index: